Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OYA 1

Drug Profile

OYA 1

Latest Information Update: 20 Mar 2020

At a glance

  • Originator OyaGen
  • Developer National Institute of Allergy and Infectious Diseases; OyaGen
  • Class Antivirals
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 16 Mar 2020 Preclinical trials in COVID-2019 infections in USA (unspecified route), prior to March 2020

Development Overview

Introduction

OYA 1 is being developed by OyaGen in collaboration with National Institute of Allergy and Infectious Diseases for the treatment of coronavirus (COVID-19) infections. OYA1 is a broad-spectrum antiviral drug and acts against coronaviruses SARS-CoV-2 and MERS-CogV. The drug is a dual target-specific antiviral against filoviruses such as Ebola virus. OyaGen plans to develop the drug in a combination therapy for COVID-2019 infections to avoid the emergence of drug-resistant virus. The OYA 1 treatment is expected to serve as a stop-gap treatment. Preclinical development in COVID-19 infections is underway in the US.

OYA 1 was approved by the US FDA for the treatment of cancer. However, due to lack of efficacy the drug was abandoned.

Key Development Milestones

In March 2020, OyaGen released preclinical data for OYA 1 in COVID-19 infections [1] .

Drug Properties & Chemical Synopsis

  • Formulation unspecified
  • Class Antivirals
  • Target Virus replication
  • Mechanism of Action Virus replication inhibitors
  • WHO ATC code

    J05A-X (Other antivirals)

  • EPhMRA code

    J5B9 (Antivirals, others)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - - Preclinical USA unspecified / unspecified National Institute of Allergy and Infectious Diseases, OyaGen 16 Mar 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
OyaGen Originator USA
OyaGen Owner USA
National Institute of Allergy and Infectious Diseases Collaborator USA

Scientific Summary

Pharmacodynamics

Preclinical studies in replicating cell culture demonstrated that OYA1 was more effective compared to the positive-control compound chlorpromazine HCl at inhibiting Coronavirus (COVID-19) infections [1] .

Development History

Event Date Update Type Comment
16 Mar 2020 Phase Change - Preclinical Preclinical trials in COVID-2019 infections in USA (unspecified route), prior to March 2020 [1] Updated 20 Mar 2020

References

  1. OyaGen, Inc. Announces a Compound in Development with Broad Antiviral Activity Against Coronaviruses, including SARS-CoV-2.

    Media Release
Back to top